Gufic Biosciences Ltd.

283.10 -2.70 ▼-0.9%

28 March 2024, 04:01:00 PM
Volume: 10,493

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.guficbio.com
Market Cap 2,833.84 Cr.
Enterprise Value(EV) 3,188.78 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 8.40 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 33.66 Trailing Twelve Months Ending 2023-12
Industry PE 41.15 Trailing Twelve Months Ending 2023-12
Book Value / Share 51.15 Trailing Twelve Months Ending 2023-12
Price to Book Value 5.52 Calculated using Price: 282.60
Dividend Yield 0.04 Period Ending 2023-03
No. of Shares Subscribed 10.03 Cr. 100,277,506 Shares
FaceValue 1
About Gufic Biosciences Ltd.
Gufic Biosciences Ltd. is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Gufic Biosciences Ltd. Delivery

Delivered Qty
Traded Qty

Gufic Biosciences Ltd. Performance

1 Day
-0.94%
1 Week
-2.21%
1 Month
-10.28%
3 Month
-12.50%
6 Month
-0.81%
1 Year
+54.61%
2 Year
+14.34%
5 Year
+271.77%
10 Year
+5142.59%

Gufic Biosciences Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 15.6 23.99 25.31 36.03 33.89 22.17 29.22 43.31 25.84
Return on Capital Employed (%) 18.38 24.24 24.26 34.1 29.65 21.01 30.05 47.29 23.23
Return on Assets (%) 3.49 5.24 5.52 8.04 8.04 5.65 10 20.98 11.54

Gufic Biosciences Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 27 34 37 54 75 129 173 269 348 391
Non Curr. Liab. 17 15 9 13 17 38 55 66 224 201
Curr. Liab. 84 104 128 169 218 326 164 186 288 378
Minority Int.
Equity & Liab. 127 152 175 235 310 493 392 521 860 969
Non Curr. Assets 36 33 31 37 46 134 131 201 396 458
Curr. Assets 91 120 143 198 264 359 261 321 464 511
Misc. Exp. not W/O
Total Assets 127 152 175 235 310 493 392 521 860 969

Gufic Biosciences Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 152 202 246 306 351 379 488 779 691 785
Other Income 1 1 1 3 4 6 4 3 3 2
Total Income 152 203 247 308 355 385 491 782 693 787
Total Expenditure -137 -183 -223 -267 -305 -327 -404 -631 -556 -641
PBIDT 15 20 24 42 50 58 88 151 137 146
Interest -4 -6 -6 -9 -10 -14 -14 -5 -8 -15
Depreciation -4 -4 -4 -4 -5 -14 -16 -19 -22 -19
Taxation -2 -3 -5 -13 -13 -7 -13 -31 -27 -28
Exceptional Items 2
PAT 4 7 9 16 22 23 44 96 80 84
Adjusted EPS 1 1 1 2 3 2 5 10 8 9

Gufic Biosciences Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 11 11 -4 -4 -5 5 47 87 106 -27
Cash Fr. Inv. -3 -2 -1 -5 -9 -13 -43 -7 -95 -191
Cash Fr. Finan. -7 -5 5 7 14 8 -4 -79 -6 234
Net Change 1 4 0 -1 1 0 0 2 5 17
Cash & Cash Eqvt 3 6 6 3 4 4 4 6 12 29

Gufic Biosciences Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 75.48 75.48 75.00 75.00 75.00 75.00 75.00 75.00 72.51
Public 24.52 24.52 25.00 25.00 25.00 25.00 25.00 25.00 27.49
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Gufic Biosciences Ltd. Announcements

Wed, 27 Mar 2024
Closure of Trading Window
Intimation of closure of trading window is attached herewith
Fri, 15 Mar 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the schedule of upcoming Analyst/ Institutional Investor meeting is attached herewith.
Thu, 14 Mar 2024
Intimation Of Grant Of Patent
Intimation of grant of Patent for an invention entitled "LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN" is attached herewith.

Gufic Biosciences Ltd. Technical Scans

Wed, 27 Mar 2024
High Delivery Percentage High Delivery Percentage
Closing Below Previous Low Closing Below Previous Low
Close Below Last Month Low Close Below Last Month Low
Closing Below Previous Low for 2 Days Closing Below Previous Low for 2 Days
Making Lower Lows for 2 Days Making Lower Lows for 2 Days

Gufic Biosciences Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 385,837.06 1,620.50 +0.8%
Cipla Ltd. 118,376.16 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 100,885.01 6,171.85 +2.0%
Zydus Lifesciences Ltd. 100,583.15 1,007.35 +0.8%
Mankind Pharma Ltd. 93,457.28 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 89,582.15 6,347.35 +1.9%
Divi's Laboratories Ltd. 89,323.54 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.32 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 31.92 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 33.82 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 54.11 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 113.49 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 64.59 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.18 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.57 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.75 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.20 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.52 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.26 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 6.85 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Gufic Biosciences Ltd. FAQ's

What is Gufic Biosciences share price?

Can I buy Gufic Biosciences shares now?

What is the Dividend Yield of Gufic Biosciences?

What is the Market Cap of Gufic Biosciences?

What are the key metrics to analyse Gufic Biosciences?

What is the 52 Week High and Low of Gufic Biosciences?

What is the trend of Gufic Biosciences share price?